Rosen Law Firm Investigates Tandem Diabetes Care Securities Fraud Claims

Written by Emily J. Thompson, Senior Investment Analyst

TNDM-4.32%

Source: Globenewswire

Updated: 1h ago

0mins

Source: Globenewswire

Securities Fraud Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing misleading business information, indicating significant deficiencies in the company's disclosure practices.
Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock fell 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting serious market concerns about the company's transparency.
Class Action Preparation: The firm is preparing a class action to seek compensation for affected investors, with no upfront costs required, which may encourage more impacted investors to participate in the legal proceedings.
Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.

TNDM

$20.16+Infinity%1D

Analyst Views on TNDM

Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Analyst Rating

7 Buy

10 Hold

0 Sell

Moderate Buy

Current: 21.070

Low

14.00

Averages

22.71

High

55.00

Current: 21.070

Low

14.00

Averages

22.71

High

55.00

Goldman Sachs

David Roman

Neutral

maintain

$16 -> $25

Al Analysis

2026-01-09

Reason

Goldman Sachs

David Roman

Price Target

$16 -> $25

Al Analysis

2026-01-09

maintain

Neutral

Reason

Goldman Sachs analyst David Roman raised the firm's price target on Tandem Diabetes to $25 from $16 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Bernstein

Market Perform

maintain

$18 -> $25

2026-01-09

Reason

Bernstein

Price Target

$18 -> $25

2026-01-09

maintain

Market Perform

Reason

Bernstein raised the firm's price target on Tandem Diabetes to $25 from $18 and keeps a Market Perform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TNDM

Unlock Now

Truist

Hold

maintain

$17 -> $24

2025-12-18

Reason

Truist

Price Target

$17 -> $24

2025-12-18

maintain

Hold

Reason

Truist raised the firm's price target on Tandem Diabetes to $24 from $17 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Canaccord

William Plovanic

Buy

maintain

$24 -> $35

2025-12-17

Reason

Canaccord

William Plovanic

Price Target

$24 -> $35

2025-12-17

maintain

Buy

Reason

Canaccord analyst William Plovanic raised the firm's price target on Tandem Diabetes to $35 from $24 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

About TNDM

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.